Breaking News Instant updates and real-time market news.

CRSP

Crispr Therapeutics

$17.07

0.36 (2.15%)

20:43
07/13/17
07/13
20:43
07/13/17
20:43

CRISPR Therapeutics initiated with a Hold at SunTrust

SunTrust analyst Peter Larson initiated CRISPR Therapeutics with a Hold and a $16 price target.

CRSP Crispr Therapeutics
$17.07

0.36 (2.15%)

03/28/17
CHDN
03/28/17
INITIATION
Target $23.5
CHDN
Buy
CRISPR Therapeutics initiated with a Buy at Chardan
Chardan analyst Madhu Kumar initiated CRISPR Therapeutics with a Buy and a $23.50 price target saying upside from clinical leadership in CRISPR therapy offsets any potential downside from its IP exposure.
02/16/17
PIPR
02/16/17
NO CHANGE
Target $21
PIPR
Overweight
Piper's Schimmer calls CRISPR selloff 'major overreaction'
Piper Jaffray analyst Joshua Schimmer views yesterday's selloff in shares of CRISPR Therapeutics (CRSP) as a "major overreaction." The stock closed yesterday down 8%, or $1.36, to $15.90 after the patent office did not allow the patent interference with UC Berkeley versus Broad Institute over a Crispr/Cas-9 patent. Now that it's deemed patentable, CRISPR will move forward to get its own claims issued and likely move towards a second interference, Schimmer tells investors in a research note. CRISPER and Intellia Therapeutics (NTLA) are essentially litigation partners against the Broad, and now have the chance to win by knocking out Editas Medicine's (EDIT) single-guide tracr patent or by showing it was the first to invent and reduce to practice the application in eukaryotes, the analyst contends. Schimmer says he can't understand why Editas' valuation is higher than CRISPR's. He believes it should be the opposite. The analyst keeps an Overweight rating on CRISPR with a $21 price target.
02/15/17
JEFF
02/15/17
NO CHANGE
JEFF
Patent ruling best case for Editas Medicine, says Jefferies
Jefferies analyst Gena Wang views the United States Patent and Trademark Office's judgment of "no interference-in-fact" for the CRISPR/Cas9 interference motion phase as the "best case" for Editas Medicine (EDIT), Broad Institute's licensee. The analyst sees three choices for The University of California, which has CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) as licensees: Appeal, seek second interference, or discuss a settlement. Wang sees cross-licensing as the likely eventual path taken by both parties. CRISPR and Intellia could license from Editas the use of CRISPR in eukaryotic cells, while Editas could license from the two companies the use of single guide and tracrRNA, the analyst tells investors in a research note. She believes a royalty could be in the mid-single-digit range. Shares of Editas are up 33% to $24.99 in afternoon while CRISPR is down 13% to $15.05 and Intellia is down 11% to $12.26.
11/15/16
SBSH
11/15/16
INITIATION
Target $19
SBSH
Neutral
CRISPR Therapeutics initiated with a Neutral at Citi
Citi analyst Yigal Nochomovitz started CRISPR Therapeutics with a Neutral rating and $19 price target. The risk/reward is balanced with the stock up 25% since the initial public offering, Nochomovitz tells investors in a research note. The analyst sees "no clear winner" in the gene editing patent debate.

TODAY'S FREE FLY STORIES

RMP

Rice Midstream

$20.33

-0.56 (-2.68%)

03:47
02/22/18
02/22
03:47
02/22/18
03:47
Downgrade
Rice Midstream rating change  »

Rice Midstream downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASND

Ascendis Pharma

$58.00

-1 (-1.69%)

03:44
02/22/18
02/22
03:44
02/22/18
03:44
Syndicate
Ascendis Pharma 3.947M share Secondary priced at $57.00 »

JPMorgan, BofA/Merrill…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

EVTC

Evertec

$16.05

-0.15 (-0.93%)

03:42
02/22/18
02/22
03:42
02/22/18
03:42
Upgrade
Evertec rating change  »

Evertec upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRI

Weingarten Realty

$27.15

-0.55 (-1.99%)

03:37
02/22/18
02/22
03:37
02/22/18
03:37
Downgrade
Weingarten Realty rating change  »

Weingarten Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

MNTA

Momenta

$16.35

0.4 (2.51%)

03:36
02/22/18
02/22
03:36
02/22/18
03:36
Upgrade
Momenta rating change  »

Momenta upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOC

Holly

03:35
02/22/18
02/22
03:35
02/22/18
03:35
Upgrade
Holly rating change  »

Holly upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLVS

Clovis

$54.93

1.22 (2.27%)

03:34
02/22/18
02/22
03:34
02/22/18
03:34
Upgrade
Clovis rating change  »

Clovis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

HST

Host Hotels

$19.22

-0.29 (-1.49%)

03:34
02/22/18
02/22
03:34
02/22/18
03:34
Upgrade
Host Hotels rating change  »

Host Hotels upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SLCA

U.S. Silica

$25.15

-5.6 (-18.21%)

03:33
02/22/18
02/22
03:33
02/22/18
03:33
Downgrade
U.S. Silica rating change  »

U.S. Silica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

JELD

Jeld-Wen

$34.50

-3.14 (-8.34%)

03:33
02/22/18
02/22
03:33
02/22/18
03:33
Downgrade
Jeld-Wen rating change  »

Jeld-Wen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Mar

TEO

Telecom Argentina

$34.09

-0.19 (-0.55%)

03:32
02/22/18
02/22
03:32
02/22/18
03:32
Downgrade
Telecom Argentina rating change  »

Telecom Argentina…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

03:30
02/22/18
02/22
03:30
02/22/18
03:30
General news
FX Action: USD-CAD clocked a two-month high »

FX Action: USD-CAD…

JELD

Jeld-Wen

$34.50

-3.14 (-8.34%)

03:27
02/22/18
02/22
03:27
02/22/18
03:27
Downgrade
Jeld-Wen rating change  »

Jeld-Wen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Mar

ALKS

Alkermes

$63.19

-1.56 (-2.41%)

03:27
02/22/18
02/22
03:27
02/22/18
03:27
Downgrade
Alkermes rating change  »

Alkermes downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSA

MSA Safety

$80.25

3.79 (4.96%)

03:25
02/22/18
02/22
03:25
02/22/18
03:25
Upgrade
MSA Safety rating change  »

MSA Safety upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

02:50
02/22/18
02/22
02:50
02/22/18
02:50
General news
FX Update: The dollar has continued to mostly trade firmer »

FX Update: The dollar…

02:15
02/22/18
02/22
02:15
02/22/18
02:15
General news
Asian Market Summary: »

Asian Market Summary:…

00:00
02/22/18
02/22
00:00
02/22/18
00:00
General news
Breaking General news story  »

Federal Reserve Vice…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

, HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

20:25
02/21/18
02/21
20:25
02/21/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

APA

Apache

$37.20

-1.1 (-2.87%)

LDOS

Leidos

$65.21

-1.02 (-1.54%)

W

Wayfair

$95.69

-0.61 (-0.63%)

OA

Orbital ATK

$131.80

-0.02 (-0.02%)

TREE

LendingTree

$371.25

-7.8 (-2.06%)

SFM

Sprouts Farmers Market

$26.12

0.12 (0.46%)

TPX

Tempur Sealy

$54.97

1.17 (2.17%)

SAFM

Sanderson Farms

$128.00

-3.44 (-2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 28

    Feb

  • 07

    Mar

  • 08

    Mar

  • 20

    Mar

  • 29

    Mar

AIMT

Aimmune

$32.21

-2.75 (-7.87%)

20:04
02/21/18
02/21
20:04
02/21/18
20:04
Syndicate
Aimmune 5.5M share Secondary priced at $32.00 »

BofA/Merrill, Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 11

    Mar

  • 22

    Feb

20:00
02/21/18
02/21
20:00
02/21/18
20:00
General news
Breaking General news story  »

Minneapolis Federal…

NUAN

Nuance

$16.28

-0.28 (-1.69%)

19:10
02/21/18
02/21
19:10
02/21/18
19:10
Periodicals
Nuance discontinues Swype feature development, Verge reports »

Nuance has ceased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SSNLF

Samsung

, QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

19:04
02/21/18
02/21
19:04
02/21/18
19:04
Hot Stocks
Samsung, Qualcomm expand foundry cooperation on EUV process technology »

Samsung Electronics…

SSNLF

Samsung

QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

CATY

Cathay General

$42.84

0.43 (1.01%)

18:59
02/21/18
02/21
18:59
02/21/18
18:59
Hot Stocks
Cathay General executive chairman Cheng sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUN

Sunoco

$30.00

-0.08 (-0.27%)

18:42
02/21/18
02/21
18:42
02/21/18
18:42
Earnings
Sunoco reports Q4 EPS $2.01, may not compare to consensus 35c »

Reports Q4 revenue $3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.